Evidence map›Paper›PMID 39579268›Full record

ArticleAnnals of nuclear medicine2025

PRIMARY scoring in 68Ga-PSMA PET/CT: correlation with prostate cancer risk groups and its potential impact on active surveillance.

Hatice Uslu, Dilruba Şahin, Ebru İbişoğlu, Mehmet Tarık Tatoğlu

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. An Innovative Approach with [Diagnostics (Basel, Switzerland) · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hatice UsluClinic of Nuclear Medicine, Istanbul Medeniyet University Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Eğitim Mah. Fahrettin Kerim Gökay Cd., 34722, Kadikoy, Istanbul, Turkey.
Dilruba ŞahinClinic of Nuclear Medicine, Istanbul Medeniyet University Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Eğitim Mah. Fahrettin Kerim Gökay Cd., 34722, Kadikoy, Istanbul, Turkey. dilrubatorun96@gmail.com.ORCID http://orcid.org/0009-0008-5709-7700
Ebru İbişoğluClinic of Nuclear Medicine, Istanbul Medeniyet University Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Eğitim Mah. Fahrettin Kerim Gökay Cd., 34722, Kadikoy, Istanbul, Turkey.
Mehmet Tarık TatoğluClinic of Nuclear Medicine, Istanbul Medeniyet University Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Eğitim Mah. Fahrettin Kerim Gökay Cd., 34722, Kadikoy, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe PRIMARY scoring system is a scale designed to identify clinically significant intraprostatic malignancies on 68Ga-PSMA PET/CT images. Active surveillance is a management method for patients with low-risk prostate cancer. In this study, we aimed to assess the efficacy of PRIMARY scoring in identifying appropriate candidates for active surveillance based on the distribution within prostate cancer risk groups.

methodsThe data of 134 patients diagnosed with PCa by biopsy who underwent 68Ga-PSMA PET/CT imaging for post-diagnostic staging purposes were retrospectively analyzed. Age, total PSA, ISUP grade, prostate lesion SUVmax values, PI-RADS scores, and PRIMARY scores were recorded. Patients were classified into low-risk and intermediate/high-risk groups.

resultsIn the intermediate/high-risk group, the PRIMARY score was 1-2 in 17.6% and 3-5 in 82.4% of patients. In the low-risk group, the PRIMARY score was 1-2 in 34.7% and 3-5 in 65.3% of patients. None of the patients in the low-risk group had a PRIMARY score of 5. The most frequent PRIMARY score in both groups was 4, and there was a significant difference between the average SUVmax values of the intermediate/high and low-risk groups with a PRIMARY score of 4 (p = 0.018). The sensitivity of PRIMARY scoring in detecting patients in the intermediate/high-risk group was 82.3%, the specificity was 34.6%, and the positive predictive value (PPV) was 68.6%. When a cut-off SUVmax value 5.0 was used for the PRIMARY score of 4, the sensitivity was 67.0%, the specificity was 65.3% and the PPV was 77.0%. In the ROC analysis, the area under the curve was 0.727 for PRIMARY scoring, 0.662 for PI-RADS, and 0.744 for their combined mean.

conclusionThe PRIMARY scoring system can complement PI-RADS scoring in mpMRI for selecting patients suitable for active surveillance. Revising the PRIMARY score 4 with an SUVmax cut-off value may increase the specificity.

Indexed as

Edetic AcidOligopeptidesPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedRetrospective StudiesEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesActive surveillanceMultiparametric MRIPET/CTProstate cancerPSMA

Identifiers

PMID39579268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.